Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

57.80 +0.13 (+0.23%)

Streaming Delayed Price Updated: 9:42 AM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

March 31, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

March 29, 2026

From Bristol Myers Squibb

Via Business Wire

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

March 28, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

March 23, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

March 20, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

March 19, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 09, 2026

From Bristol Myers Squibb

Via Business Wire

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 06, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend

March 02, 2026

From Bristol Myers Squibb

Via Business Wire

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

From Bristol Myers Squibb

Via Business Wire

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

February 17, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

February 05, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

February 04, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care

February 03, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

January 20, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

January 12, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 02, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

December 08, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 04, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

December 03, 2025

From Bristol Myers Squibb

Via Business Wire

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

Via Investor Brand Network

Topics Government

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

December 01, 2025

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.